HIV-1 antiretroviral drug therapy

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 4, 2012, Pages

  Arts, Eric J ^a   Hazuda, Daria J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACICLOVIR; AMANTADINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ENTECAVIR; FAMCICLOVIR; FOSAMPRENAVIR; FOSCARNET SODIUM; GANCICLOVIR; IBALIZUMAB; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; OSELTAMIVIR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZANAMIVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 84865375176     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007161     Document Type: Article

References (168)

1. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. 2010. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84: 9864-9878.
2. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, BergerEA. 1996. CC CKR5: A RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
3. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, et al. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 18: 835-838.
4. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
5. + T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
6. Baba M, Miyake H, Wang X, Okamoto M, Takashima K. 2007. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 51: 707-715.
7. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, et al. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44: 2475-2484.
8. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, et al. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75: 4999-5008.
9. Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 78: 12428-12437.
10. Balzarini J, Herdewijn P, De Clercq E. 1989. Differential patterns of intracellular metabolism of 2′, 3′-didehydro-2′, 3′-dideoxythymidine and 3′-azido-2′, 3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 264: 6127-6133.
11. Berkhout B. 1999. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness. J Biomed Sci 6: 298-305.
12. Biscone MJ, Miamidian JL, Muchiri JM, Baik SS, Lee FH, Doms RW, Reeves JD. 2006. Functional impact of HIV coreceptor-binding site mutations. Virology 351: 226-236.
13. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165: 105-110.
14. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 75: 4832-4842.
15. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17: F1-F5.
16. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
17. Cheng YC, Dutschman GE, Bastow KF, Sarngadharan MG, Ting RY. 1987. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Mol Biol 262: 2187-2189.
18. Clavel F, Race E, Mammano F. 2000. HIV drug resistance and viral fitness. Adv Pharmacol 49: 41-66.
19. Coffin JM. 1995. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
20. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, JonesM, Facey K, Whitacre C, McAuliffe VJ, et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334: 1011-1017.
21. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374: 569-571.
22. Craigie R, Bushman FD. 2011. HIV DNA integration. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006890.
23. Cupelli LA, Hsu MC. 1995. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol 69: 2640-2643.
24. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, et al. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 124: 1019-1030.
25. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
26. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S. 2008. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 22: 665-666.
27. Davidson A, Leeper TC, Athanassiou Z, Patora-Komisarska K, Karn J, RobinsonJA, Varani G. 2009. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci 106: 11931-11936.
28. Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE. 1964. Antiviral activity of 1-adamantanamine (amantadine). Science 144: 862-863.
29. Deeks SG. 2001. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26: S25-S33.
30. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC. 2000. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 44: 794-797.
31. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 381: 661-666.
32. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
33. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 279: 509-516.
34. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158.
35. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. 2005. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
36. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70: 3763-3769.
37. Doyon L, Payant C, Brakier-Gingras L, Lamarre D. 1998. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72: 6146-6150.
38. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, et al. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci 97: 5639-5644.
39. Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285: 193-203.
40. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, et al. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci 97: 11244-11249.
41. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
42. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, QuinnTC, Chadwick K, Margolick J, Brookmeyer R, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
43. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
44. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W. 2009. Loss of Raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J Virol 83: 11440-11446.
45. Frost SD, McLean AR. 1994. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8: 323-332.
46. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, JanzenWP, Chen IS, Lee KH. 1994. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57: 243-247.
47. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, LehrmanSN, Bolognesi DP, Broder S, Mitsuya H. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci 83: 8333-8337.
48. Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C, Mugyenyi P, Petropoulos C, Arts EJ. 2004. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. J Virol 78: 5390-5401.
49. Garcia-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 77: 5685-5693.
50. Garrido C, Geretti A, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C, et al. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 65: 320-326.
51. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, GeluykensP, Dockx K, Strijbos R, Smits V, Vos A, et al. 2008. Resistance mutations in HIV type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 82: 10366-10374.
52. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, et al. 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci 99: 6661-6666.
53. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J, Klimkait T. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci 94: 3548-3553.
54. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci 107: 20057-20062.
55. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A, Larder BA. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 70: 5930-5934.
56. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, Cameron JM. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 36: 1688-1694.
57. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4: 3021-3024.
58. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr., Egbertson MS, et al. 2004a. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci 101: 11233-11238.
59. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, HandtL, Motzel SL, Klein HJ, et al. 2004b. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305: 528-532.
60. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, JacksonJB, Coombs RW, Glesby MJ, Flexner CW, et al. 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262.
61. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373: 123-126.
62. Hsiou Y, Ding J, Das K, Clark AD Jr., Hughes SH, Arnold E. 1996. Structure of unliganded HIV-1 reverse transcriptase at 2. 7 A resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure 4: 853-860.
63. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ. 1991. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254: 1799-1802.
64. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, ErdmanK, Brown F, Sun E, Leonard JM. 1998. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63: 453-464.
65. Hu W-S, Hughes SH. 2011. HIV-1 reverse transcription. Cold Spring Harb Perspect Med doi: 10/1101/cshperspect. a006882.
66. Huang H, Chopra R, Verdine GL, Harrison SC. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282: 1669-1675.
67. Hwang S, Tamilarasu N, Kibler K, Cao H, Ali A, Ping YH, Jeang KT, Rana TM. 2003. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem 278: 39092-39103.
68. Imamichi T, Murphy MA, Imamichi H, Lane HC. 2001. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J Virol 75: 3988-3992.
69. Karn J, Stoltzfus CM. 2011. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006916.
70. Kellam P, Boucher CA, Larder BA. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci 89: 1934-1938.
71. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, et al. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41: 654-660.
72. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, et al. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307.
73. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312: 767-768.
74. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. 1992. Crystal structure at 3. 5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790.
75. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4: 953-956.
76. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M. 2008. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73: 789-800.
77. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, MorrisD, Hubbel E, Chee M, et al. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 2: 753-759.
78. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, StrizkiJM, Riley J, Baroudy BM, Wilson IA, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 78: 2790-2807.
79. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V Jr., et al. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 189: 286-291.
80. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F, MammanoF. 2003. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 77: 1610-1613.
81. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr., et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185.
82. Lalonde M, Lobritz M, Ratcliff A, Chaminian M, Athanassiou Z, Tyagi M, Karn J, Robinson JA, Varani G, Arts EJ. 2011. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog 7: e1002038.
83. Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X. 2010. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): Implications for drug design. J Med Chem 53: 4295-4299.
84. Larder BA, Kemp SD. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
85. Larder BA, Kemp SD, Harrigan PR. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
86. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, et al. 1998. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 178: 70-79.
87. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, et al. 2003. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci 100: 13555-13560.
88. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, et al. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci 100: 11013-11018.
89. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ. 2007. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol 81: 8258-8269.
90. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. 1998. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J Mol Biol 282: 359-68.
91. Malashkevich VN, Chan DC, Chutkowski CT, Kim PS. 1998. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci 95: 9134-9139.
92. Malim MH, Bieniasz PD. 2011. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006940.
93. Mammano F, Petit C, Clavel F. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 72: 7632-7637.
94. Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
95. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V. 2004. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72: 162-165.
96. Marinello J, Marchand C, Mott B, Bain A, Thomas CJ, Pommier Y. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47: 9345-54.
97. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16: 1227-1235.
98. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ. 2005. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 79: 7121-7134.
99. McColl DJ, Chen X. 2010. Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Res 85: 101-118.
100. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. 1999. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell Biol 4: 35-43.
101. Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, Scott WA. 2002. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 46: 1540-1545.
102. Miller V. 2001. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 26 (Suppl 1): S34-S50.
103. Mitsuya H, Broder S. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′, 3′-dideoxynucleosides. Proc Natl Acad Sci 83: 1911-1915.
104. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci 82: 7096-7100.
105. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, MarkowitzM, Chernyavskiy T, Niu P, Lyons N, et al. 1996a. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2: 760-766.
106. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, MarkowitzM, Chernyavskiy T, Niu P, Lyons N, et al. 1996b. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2: 760-766.
107. Naeger LK, Margot NA, Miller MD. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 46: 2179-2184.
108. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. 2001. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183: 1121-1125.
109. Nijhuis M, Deeks S, Boucher C. 2001. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 14: 23-28.
110. Nowak MA, Bonhoeffer S, Shaw GM, May RM. 1997. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations. J Theor Biol 184: 203-217.
111. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. 2002. Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem 277: 38053-38061.
112. Parikh UM, Bacheler L, Koontz D, Mellors JW. 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 80: 4971-4977.
113. Park J, Morrow CD. 1993. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology 194: 843-850.
114. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. 1582-1586.
115. Quan Y, Gu Z, Li X, Li Z, Morrow CD, Wainberg MA. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 70: 5642-5645.
116. Quercia R, Dam E, Perez-Bercoff D, Clavel F. 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. Virol J 83: 10245-10249.
117. Quinones-Mateu ME, Arts EJ. 2002. Fitness of drug resistant HIV-1: Methodology and clinical implications. Drug Resist Updat 5: 224-233.
118. Quinones-Mateu ME, Arts EJ. 2006. Virus fitness: Concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 299: 83-140.
119. Quinones-Mateu ME, Moore-Dudley DM, Jegede O, Weber J, Arts J. 2008. Viral drug resistance and fitness. Adv Pharmacol 56: 257-296.
120. Ray PE, Soler-Garcia AA, Xu L, Soderland C, Blumenthal R, Puri A. 2005. Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatr Nephrol 20: 1401-1409.
121. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, PohlmannS, Sfakianos JN, Derdeyn CA, Blumenthal R, et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci 99: 16249-16254.
122. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW. 2004. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 78: 5476-5485.
123. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. 2005. Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79: 4991-4999.
124. Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, Miatkowski K, Olson D, Parish TH, Rosa MD, et al. 1997. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 13: 933-943.
125. Richman DD. 2001. HIV chemotherapy. Nature 410: 995-1001.
126. Rimsky LT, Shugars DC, Matthews TJ. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72: 986-993.
127. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, Harrison SC. 1995. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci 92: 1222-1226.
128. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, et al. 2006. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 49: 1506-1508.
129. Schinazi RF, Lloyd RM Jr., Nguyen MH, Cannon DL, McMillan A, Ilksoy N, ChuCK, Liotta DC, Bazmi HZ, Mellors JW. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37: 875-881.
130. Shafer RW, Dupnik K, Winters MA, Eshleman SH. 2000. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. InHIV sequence compendium 2000 (ed. Kuiken CL, et al.). Los Alamos National Laboratory, Los Alamos, NM.
131. Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. 2005. Antiretroviral compounds: Mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem 12: 1705-1719.
132. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, et al. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82: 764-774.
133. Singh I, Gorzynski J, Drobysheva D, Bassit L, Schinazi R. 2010. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 5: e9948. doi: 10. 1371/journal. pone. 0009948.
134. Sluis-Cremer N, Temiz NA, Bahar I. 2004. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2: 323-332.
135. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE. 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′, 3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 51: 3574-3581.
136. Spence RA, Kati WM, Anderson KS, Johnson KA. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267: 988-993.
137. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. 2003. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51: 229-240.
138. Staszewski S, Miller V, Rehmet S, Stark T, De CJ, De BM, Peeters M, Andries K, Moeremans M, De RM, et al. 1996. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10: F1-F7.
139. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, Furman PA. 1987. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31: 1972-1977.
140. Stengel RF. 2008. Mutation and control of the human immunodeficiency virus. Math Biosci 213: 93-102.
141. Sundquist WI, Kräusslich H-G. 2011. Assembly, budding, and maturation. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. 1006924.
142. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, PauwelsR, Andries K, Janssen PA, Arnold EA. et al. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 243: 369-387.
143. Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ. 2010. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: Impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol 84: 9817-9830.
144. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quinones-Mateu ME, Arts EJ. 2000. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 74: 4868-4876.
145. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. 2000. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 25: 99-102.
146. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, XuS, Wojcik L, Tagat J, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci 99: 395-400.
147. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, PalaniA, Clader JW, Tagat JR, et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77: 5201-5208.
148. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, et al. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82: 8210-8214.
149. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. 2008. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir elvitegravir phenotypic susceptibility. AIDS 22: 1877-80.
150. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr., Kunstman K, KuhmannSE, Marx PA, Lifson JD, Dufour J, et al. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 198: 1551-1562.
151. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, et al. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (London)438: 99-102.
152. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4: 87-94.
153. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373: 117-122.
154. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
155. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
156. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359-2371.
157. White KL, Chen JM, Feng JY, Margot NA, Ly JK, Ray AS, Macarthur HL, McDermott MJ, Swaminathan S, Miller MD. 2006. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antiviral Therapy 11: 155-163.
158. Wild C, Greenwell T, Matthews T. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9: 1051-1053.
159. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci 91: 9770-9774.
160. Wilen CB, Tilton JC, Doms RW. 2011. HIV: Cell binding and entry. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006866.
161. Wingfield WL, Pollack D, Grunert RR. 1969. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281: 579-584.
162. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13: 1477-1483.
163. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
164. Yahi N, Fantini J, Henry M, Tourres C, Tamalet C. 2005. Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy. J Biomed Sci 12: 701-710.
165. Young FE. 1988. The role of the FDA in the effort against AIDS. Public Health Rep 103: 242-245.
166. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72: 3300-3306.
167. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71: 6662-6670.
168. Zhou T, Xu L, Dey B, Hessell AJ, Van RD, Xiang SH, Yang X, Zhang MY, ZwickMB, Arthos J, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.